Peregrine Asset Advisers Inc. purchased a new stake in Novartis AG (NYSE:NVS) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 3,300 shares of the company’s stock, valued at approximately $283,000.

Other institutional investors have also recently bought and sold shares of the company. Janus Henderson Group PLC lifted its stake in Novartis AG by 42,797.5% in the second quarter. Janus Henderson Group PLC now owns 1,914,516 shares of the company’s stock valued at $159,821,000 after buying an additional 1,910,053 shares during the period. Parnassus Investments CA lifted its stake in Novartis AG by 18.5% in the third quarter. Parnassus Investments CA now owns 9,447,817 shares of the company’s stock valued at $811,095,000 after buying an additional 1,477,168 shares during the period. FMR LLC lifted its stake in Novartis AG by 172.1% in the second quarter. FMR LLC now owns 2,294,782 shares of the company’s stock valued at $191,546,000 after buying an additional 1,451,441 shares during the period. Principal Financial Group Inc. acquired a new position in Novartis AG in the second quarter valued at about $71,606,000. Finally, BlackRock Inc. lifted its stake in Novartis AG by 25.3% in the second quarter. BlackRock Inc. now owns 3,549,783 shares of the company’s stock valued at $296,299,000 after buying an additional 717,186 shares during the period. Institutional investors and hedge funds own 10.74% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.watchlistnews.com/peregrine-asset-advisers-inc-purchases-new-holdings-in-novartis-ag-nvs/1724189.html.

Novartis AG (NYSE:NVS) traded up $0.20 during midday trading on Friday, hitting $84.48. The stock had a trading volume of 1,540,300 shares, compared to its average volume of 2,325,532. The firm has a market capitalization of $199,845.47, a price-to-earnings ratio of 17.78, a P/E/G ratio of 2.69 and a beta of 0.72. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08. Novartis AG has a 52 week low of $66.93 and a 52 week high of $86.90.

Novartis AG (NYSE:NVS) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, topping the Zacks’ consensus estimate of $1.25 by $0.04. The company had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. Novartis AG had a return on equity of 15.77% and a net margin of 13.73%. Novartis AG’s revenue was up 2.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.23 earnings per share. analysts anticipate that Novartis AG will post 4.75 EPS for the current fiscal year.

Several equities analysts have weighed in on the company. J P Morgan Chase & Co reissued a “neutral” rating on shares of Novartis AG in a research note on Tuesday, September 5th. BidaskClub raised Novartis AG from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Cowen Inc set a $90.00 target price on Novartis AG and gave the company a “hold” rating in a research note on Wednesday, August 9th. Leerink Swann increased their target price on Novartis AG from $89.00 to $91.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Finally, Zacks Investment Research lowered Novartis AG from a “buy” rating to a “hold” rating in a research note on Friday, October 6th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $85.32.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.